Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)

Tom Kornhauser*, Roy Schwartz, Michaella Goldstein, Meira Neudorfer, Anat Loewenstein, Adiel Barak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To assess the efficacy and safety of intraocular injections of bevacizumab in patients with macular edema (ME) following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Methods: Retrospective, non-comparative case series. Patients ≥18 years of age with ME secondary to BRVO or CRVO who received a minimum of one intravitreal injection of bevacizumab with a follow-up >3 months were included. Primary endpoints were mean change in best corrected visual acuity (BCVA) from baseline to 12 and 24 months, and mean change in central macular thickness (CMT) after 3 injections. Secondary endpoints were mean change in BCVA and CMT from baseline to end of follow-up, number of injections, and ocular adverse events. Results: Eighty-seven eyes with BRVO and 65 eyes with CRVO were included. Mean follow-up time was 24.4 and 26.1 months in the BRVO and CRVO groups, respectively. The mean change in BCVA was 0.25 LogMAR in the BRVO group and −0.118 LogMAR in the CRVO group. Conclusion: Visual acuity outcomes in the CRVO group were poorer, especially in patients with low baseline BCVA.

Original languageEnglish
Pages (from-to)835-844
Number of pages10
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume254
Issue number5
DOIs
StatePublished - 1 May 2016

Keywords

  • BRVO
  • Bevacizumab
  • CME
  • CRVO
  • Injections
  • RVO

Fingerprint

Dive into the research topics of 'Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)'. Together they form a unique fingerprint.

Cite this